mercredi 10 octobre 2018

Onco Actu du 10 octobre 2018

1. Biologie

Stanford shows that breast cancers punch tunnels into neighboring tissue [Stanford]

1.4 Biologie - Technos

As it moves out of the lab, CRISPR brings tough questions into the clinic [STAT]

Gene Editing: Freely You Have Received, Freely Give [In the Pipeline]

5. Traitements

Drug sensitivity and resistance testing could make ‘right to try’ a real thing [STAT]

5.10 Traitements - Essais

UK clinical trials fall as Brexit clouds drug approval process [Reuters]

Ghost authorship haunts industry-funded clinical trials [Nature]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Supercharged natural killer cells may hold promise for cancer [Imperial College London]

Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold [Affimed]

One of Affimed’s new glass slippers cracks as a deadly incident forces halt to PhI cancer trials [EndPoints]

5.12.3 Immunothérapies-combinaisons

Neoadjuvant combination checkpoint blockade trial yields high response rates for patients with high-risk stage 3 melanoma [MD Anderson Cancer Center]

Checkpoint therapies before surgery? MD Anderson team reports encouraging efficacy but worries about toxicity [EndPoints]

5.12.8 Immunothérapies - Economie

Rgenix bags $40M to advance cancer drugs, including GSK castoff [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

Update on EMA’s Brexit preparedness [EMA]

5.4 Traitements - Economie

China approves 17 anti-cancer drugs for medical insurance coverage [Reuters]

5.6 ESMO

Incyte Announces Data for Pemigatinib, its Selective FGFR Inhibitor, to be Featured at the ESMO 2018 Congress [Incyte]

Loxo Oncology Announces Details for Data Presentations at the European Society for Medical Oncology 2018 Congress [Loxo Oncology]

Merck’s Broad Oncology Pipeline to Be Highlighted at ESMO 2018 Congress [Merck]

AstraZeneca presents advances in improving treatment options for ovarian and lung cancer patients at ESMO 2018 Congress [AstraZeneca]

5.6.11 ESMO- Rein

AVEO Oncology To Present Updated Interim Results From The Phase 2 Portion Of The TiNivo Study Of Tivozanib And Nivolumab (OPDIVO®) In RCC At The ESMO 2018 Annual Congress [Aveo]

5.6.14 ESMO - Ovaire

TESARO Announces Data Presentations at the ESMO 2018 Congress [Tesaro]

6. Lutte contre les cancers

Joe Biden delivers inaugural cancer research lecture at Imperial [Imperial College London]

6.6 Publications

How to write a thorough peer review [Nature]

6.8 Communication

'Fry and Turnbull effect' on prostate cancer [BBC News]

6.9 Controverses

Was cancer scientist fired for challenging lab chief over authorship? [Science]